Serum PCSK9 levels in infants with deviant birth weight: a biomarker of the lipoprotein metabolism

Vlahos, Antonios P.; Rallis, Dimitrios; Lianou, Alexandra; Baltogianni, Maria; Dermitzaki, Niki; Maragoudaki, Eleni; Papastergiou, Eleni; Tzallas, C.; Tsabouri, Sophia; Makis, Alexandros; Siomou, Ekaterini; Milionis, H. J.; Giapros, Vasileios

doi:10.1080/14767058.2023.2188108

Cited by 1 publication

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher circulating PCSK9 levels were found in obese compared with nonobese adult subjects [ 46 , 47 ], and female obese subjects with type 2 diabetes had the highest levels of PCSK9 within a group of young adults aged 15 to 26 years [ 9 ]. Taken together, these previous studies support that female sex and proinflammatory states such as overweight/obesity status, as well as intrauterine growth restriction and prematurity are associated with higher circulating PSCK9 concentrations, suggesting a possible impact of estrogens, epigenetics, and gestational maturation on metabolic states [ 12-14 ]. In our study, cord blood PCSK9 concentration was significantly associated with maternal overweight/obesity status, after adjusting for GA, birth weight, sex, and intrauterine growth restriction.…”

Section: Discussionmentioning

confidence: 55%

“…Moreover, PCSK9 was previously associated with urgent cesarean delivery [ 31 ]. Previous studies in neonates showed that PCSK9 concentrations were significantly higher in neonates born small or large for GA compared with neonates born appropriate for GA. Also, PCSK9 concentrations in neonates showed a significant correlation with total and LDL cholesterol [ 12 ]. Another study in newborns showed that neonatal PCSK9 concentrations were a significant predictor of fetal LDL-cholesterol levels independent of small-for-GA status in multivariate analysis [ 13 ].…”

Section: Discussionmentioning

confidence: 99%

“…The large molecular weight of PCSK9 likely precludes its transplacental transfer, but PCSK9 is detectable in cord blood and may regulate fetal lipid levels [ 10 , 11 ]. Previous studies showed that PCSK9 concentrations in cord blood or the serum of high-risk neonates (ie, neonates born premature, with intrauterine growth restriction, or small or large for gestational age [GA]) differ significantly compared with neonates born at term, without growth restriction, or with appropriate birth weight for GA [ 12-14 ]. However, the impact of maternal overweight/obesity and/or diabetes on the concentrations of PCSK9 in the neonatal-placental circulation is unknown.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Maternal Obesity Modulates Cord Blood Concentrations of Proprotein Convertase Subtilisin/Kexin-type 9 Levels

Rallis,

Papathanasiou,

Christou

2024

Journal of the Endocrine Society

Self Cite

View full text Add to dashboard Cite

Context In utero exposure to maternal obesity or diabetes is considered a pro-inflammatory state. Objective To evaluate whether cord blood Proprotein Convertase Subtilisin/Kexin-Type 9 (PCSK9), that is regulated by inflammation and metabolic derangements, is elevated in neonates born to overweight, obese, or diabetic mothers. Methods A retrospective study in full-term neonates born between 2010 and 2023, at Brigham and Women’s Hospital. There were 116 neonates included in our study, of which 74 (64%) were born to overweight/obese mothers and 42 (36%) were born to non-overweight/non-obese mothers. Results Neonates born to overweight/obese mothers had significantly higher cord blood concentrations of PCSK9 compared to neonates born to non-overweight/non-obese group [323 (253-442) ng/ml compared to 270 (244-382) ng/ml, p=0.041]. We found no significant difference in cord blood concentrations of PCSK9 between neonates of diabetic mothers compared to neonates of non-diabetic mothers. In multivariate linear regression analysis, higher cord plasma PCSK9 concentration was significantly associated with maternal overweight/obesity status (b=50.12, 95%CI 4.02-96.22, p=0.033), after adjusting for gestational age, birth weight, male sex, and intrauterine growth restriction. Conclusion Neonates born to mothers with overweight/obesity have higher cord blood PCSK9 concentrations compared to non-overweight/non-obese group and higher cord blood PCSK9 concentrations were significantly associated with maternal overweight/obesity status, after adjusting for perinatal factors. Larger longitudinal studies are needed to examine the role of PCSK9 in the development of metabolic syndrome in high-risk neonates born to overweight, obese, or diabetic mothers.

show abstract